These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 38072311)

  • 21. Hemagglutinating virus of Japan-envelope containing programmed cell death-ligand 1 siRNA inhibits immunosuppressive activities and elicits antitumor immune responses in glioma.
    Sugii N; Matsuda M; Okumura G; Shibuya A; Ishikawa E; Kaneda Y; Matsumura A
    Cancer Sci; 2021 Jan; 112(1):81-90. PubMed ID: 33155337
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic targeting of tumor-associated myeloid cells synergizes with radiation therapy for glioblastoma.
    Zhang P; Miska J; Lee-Chang C; Rashidi A; Panek WK; An S; Zannikou M; Lopez-Rosas A; Han Y; Xiao T; Pituch KC; Kanojia D; Balyasnikova IV; Lesniak MS
    Proc Natl Acad Sci U S A; 2019 Nov; 116(47):23714-23723. PubMed ID: 31712430
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Suppressing PD-L1 Expression via AURKA Kinase Inhibition Enhances Natural Killer Cell-Mediated Cytotoxicity against Glioblastoma.
    Nguyen TTT; Gao Q; Mun JY; Zhu Z; Shu C; Naim A; Rogava M; Izar B; Westhoff MA; Karpel-Massler G; Siegelin MD
    Cells; 2024 Jul; 13(13):. PubMed ID: 38995006
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The levels of immunosuppressive checkpoint protein PD-L1 and tumor-infiltrating lymphocytes were integrated to reveal the glioma tumor microenvironment.
    Zhang W; Liu L; Liu X; Han C; Li Q
    Environ Toxicol; 2024 Feb; 39(2):815-829. PubMed ID: 37792606
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme.
    Heynckes S; Daka K; Franco P; Gaebelein A; Frenking JH; Doria-Medina R; Mader I; Delev D; Schnell O; Heiland DH
    BMC Cancer; 2019 Feb; 19(1):117. PubMed ID: 30709339
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting the PD-1/PD-L1 pathway in glioblastoma multiforme: Preclinical evidence and clinical interventions.
    Maghrouni A; Givari M; Jalili-Nik M; Mollazadeh H; Bibak B; Sadeghi MM; Afshari AR; Johnston TP; Sahebkar A
    Int Immunopharmacol; 2021 Apr; 93():107403. PubMed ID: 33581502
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Myeloid-Derived Suppressive Cells Promote B cell-Mediated Immunosuppression via Transfer of PD-L1 in Glioblastoma.
    Lee-Chang C; Rashidi A; Miska J; Zhang P; Pituch KC; Hou D; Xiao T; Fischietti M; Kang SJ; Appin CL; Horbinski C; Platanias LC; Lopez-Rosas A; Han Y; Balyasnikova IV; Lesniak MS
    Cancer Immunol Res; 2019 Dec; 7(12):1928-1943. PubMed ID: 31530559
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Autophagy-related CMTM6 promotes glioblastoma progression by activating Wnt/β-catenin pathway and acts as an onco-immunological biomarker.
    Dai L; Xiao J; Li X; Tao Y; Zhou P; Lyu L; Shi Z; Liang X; Jia Z; Jiang S
    J Gene Med; 2024 May; 26(5):e3685. PubMed ID: 38686653
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quantitative analysis of immune cells within the tumor microenvironment of glioblastoma and their relevance for prognosis.
    Wang L; He Z; Fan S; Mo L; Li Y; Yuan X; Xu B; Mou Y; Yin Y
    Int Immunopharmacol; 2024 Dec; 142(Pt A):113109. PubMed ID: 39255678
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma.
    Antonios JP; Soto H; Everson RG; Moughon D; Orpilla JR; Shin NP; Sedighim S; Treger J; Odesa S; Tucker A; Yong WH; Li G; Cloughesy TF; Liau LM; Prins RM
    Neuro Oncol; 2017 Jun; 19(6):796-807. PubMed ID: 28115578
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Systematic Review of the Tumor-Infiltrating CD8
    Shadbad MA; Asadzadeh Z; Hosseinkhani N; Derakhshani A; Alizadeh N; Brunetti O; Silvestris N; Baradaran B
    Front Immunol; 2021; 12():734956. PubMed ID: 34603316
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rapid tumor recurrence in a novel murine GBM surgical model is associated with Akt/PD-L1/vimentin signaling.
    Liu F; Xu XH; Li CY; Zhang TT; Yin SL; Liu GQ; Hu F; Yu SB; Chen XQ
    Biochem Biophys Res Commun; 2021 Sep; 569():1-9. PubMed ID: 34216991
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of novel peptide-based radiotracers for detecting PD-L1 expression and guiding cancer immunotherapy.
    Zhu S; Liang B; Zhou Y; Chen Y; Fu J; Qiu L; Lin J
    Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):625-640. PubMed ID: 37878029
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ACT001 reduces the expression of PD-L1 by inhibiting the phosphorylation of STAT3 in glioblastoma.
    Tong L; Li J; Li Q; Wang X; Medikonda R; Zhao T; Li T; Ma H; Yi L; Liu P; Xie Y; Choi J; Yu S; Lin Y; Dong J; Huang Q; Jin X; Lim M; Yang X
    Theranostics; 2020; 10(13):5943-5956. PubMed ID: 32483429
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas.
    Zeng J; See AP; Phallen J; Jackson CM; Belcaid Z; Ruzevick J; Durham N; Meyer C; Harris TJ; Albesiano E; Pradilla G; Ford E; Wong J; Hammers HJ; Mathios D; Tyler B; Brem H; Tran PT; Pardoll D; Drake CG; Lim M
    Int J Radiat Oncol Biol Phys; 2013 Jun; 86(2):343-9. PubMed ID: 23462419
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models.
    Puigdelloses M; Garcia-Moure M; Labiano S; Laspidea V; Gonzalez-Huarriz M; Zalacain M; Marrodan L; Martinez-Velez N; De la Nava D; Ausejo I; Hervás-Stubbs S; Herrador G; Chen Z; Hambardzumyan D; Patino Garcia A; Jiang H; Gomez-Manzano C; Fueyo J; Gállego Pérez-Larraya J; Alonso M
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34281988
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PD-L1 confers glioblastoma multiforme malignancy via Ras binding and Ras/Erk/EMT activation.
    Qiu XY; Hu DX; Chen WQ; Chen RQ; Qian SR; Li CY; Li YJ; Xiong XX; Liu D; Pan F; Yu SB; Chen XQ
    Biochim Biophys Acta Mol Basis Dis; 2018 May; 1864(5 Pt A):1754-1769. PubMed ID: 29510196
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nanoparticle-mediated blockade of CXCL12/CXCR4 signaling enhances glioblastoma immunotherapy: Monitoring early responses with MRI radiomics.
    Wei R; Li J; Lin W; Pang X; Yang H; Lai S; Wei X; Jiang X; Yuan Y; Yang R
    Acta Biomater; 2024 Mar; 177():414-430. PubMed ID: 38360292
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PTRF/Cavin-1 as a Novel RNA-Binding Protein Expedites the NF-κB/PD-L1 Axis by Stabilizing lncRNA NEAT1, Contributing to Tumorigenesis and Immune Evasion in Glioblastoma.
    Yi K; Cui X; Liu X; Wang Y; Zhao J; Yang S; Xu C; Yang E; Xiao M; Hong B; Fang C; Kang C; Tan Y; Wang Q
    Front Immunol; 2021; 12():802795. PubMed ID: 35069587
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Upregulation of HLA-II related to LAG-3
    Guo W; Peng D; Liao Y; Lou L; Guo M; Li C; Yu W; Tian X; Wang G; Lv P; Zuo J; Shen H; Li Y
    Cancer Sci; 2024 May; 115(5):1388-1404. PubMed ID: 38480275
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.